Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
AGIO reported Form 144 sale/transfer activity tied to executive restricted stock units. The filing lists 19,068 shares associated with vesting of RSUs on 04/02/2026 and discloses a prior sale of 18,055 shares on 03/02/2026 for $522,873.
AGIO submitted a Form 144 notice to sell 3,141 shares of Common Stock tied to the vesting of Restricted Stock Units on 04/02/2026. The excerpt also shows a prior sale by Cecilia Jones of 5,035 shares on 03/02/2026.
AGIO Therapeutics reported a notice under Rule 144 for common stock related to an insider transaction. The filing shows 2,959 shares tied to the vesting of Restricted Stock Units on 04/02/2026. The filing also records that Krishnan Viswanadhan had 2,959 shares listed under "Securities Sold During The Past 3 Months" with an associated dollar figure of $82,260.00 dated 03/05/2026.
AGIO affiliate filed a Form 144 notice for proposed sales of Common Stock tied to the vesting of restricted stock units on 04/02/2026. The filing lists quantities and dollar values for recent sales by Tsveta Milanova, including 2,868 shares ($83,057.00) on 03/02/2026 and 2,872 shares ($77,601.00) on 01/05/2026.
AGIO Pharmaceuticals reported a proposed sale of 2,940 shares of Common Stock under a Form 144 notice dated 04/02/2026, arising from the vesting of Restricted Stock Units. The filing also reports a prior sale of 4,055 shares on 03/02/2026.
The Form 144 lists the broker Morgan Stanley Smith Barney LLC and shows monetary figures adjacent to the share entries. The filing documents a routine affiliate sale notice tied to RSU vesting.
AGIO filed a Form 144 reporting the vesting of 3,280 restricted stock units on 04/02/2026. The filing also records a prior sale of 5,218 shares by James Burns on 03/02/2026, shown under "Securities Sold During The Past 3 Months."
The Vanguard Group filed Amendment No. 10 to Schedule 13G/A reporting zero beneficial ownership of Agios Pharmaceuticals Inc. common stock as of 03/13/2026. The filing explains an internal realignment effective January 12, 2026, that disaggregated beneficial ownership among Vanguard subsidiaries.
Agios Pharmaceuticals executive Krishnan Viswanadhan, Chief Corp Dev & Strategy, reported several equity transactions on March 5, 2026 tied to restricted stock units (RSUs). He exercised 8,100 RSUs, converting them into 8,100 shares of common stock at a price of $0.00 per share, reflecting the nature of RSUs as equity awards rather than open-market purchases. Following this, 2,959 common shares were sold at $27.80 per share to cover tax withholding obligations related to the RSU vesting, under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he directly held 16,200 RSUs and 5,141 common shares. The RSUs were granted on March 5, 2025, with the underlying shares scheduled to vest in three equal annual installments beginning March 5, 2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 reporting a proposed resale related to the vesting of 2,959 Restricted Stock Units into Common Stock. The vesting and proposed sale date is 03/05/2026, and the shares are listed on Nasdaq.
AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.